Search

Your search keyword '"Saba Villarroel, Paola Mariela"' showing total 25 results
Start Over Author "Saba Villarroel, Paola Mariela"
25 results on '"Saba Villarroel, Paola Mariela"'

7. Heterogeneous SARS-CoV-2 humoral response after COVID-19 vaccination and/or infection in the general population

Author

Carrat, Fabrice, Saba Villarroel, Paola Mariela, Lapidus, Nathanaël, Fourié, Toscane, Blanché, Hélène, Dorival, Céline, Nicol, Jérôme, Deleuze, Jean-François, Robineau, Olivier, Touvier, Mathilde, Severi, Gianluca, Zins, Marie, de Lamballerie, Xavier, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Unité des Virus Emergents (UVE), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d'Etude du Polymorphisme Humain (CEPH), Institut Universitaire d'Hématologie (IUH), Université Paris Diderot - Paris 7 (UPD7)-Université Paris Diderot - Paris 7 (UPD7)-Fondation Jean Dausset-Université Paris Cité (UPCité), Equipe 3: EREN- Equipe de Recherche en Epidémiologie Nutritionnelle (CRESS - U1153), Université Sorbonne Paris Nord-Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Cohortes épidémiologiques en population (CONSTANCES), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay-Université Paris Cité (UPCité), UFR Médecine [Santé] - Université Paris Cité (UFR Médecine UPCité), Université Paris Cité (UPCité), This study ANR (Agence Nationale de la Recherche, #ANR-20-COVI-000, #ANR-10-COHO-06), Fondation pour la Recherche Médicale (#20RR052-00), Inserm (Institut National de la Santé et de la Recherche Médicale, #C20-26). The sponsor and funders facilitated data acquisition but did not participate in the study design, analysis, interpretation or drafting. Cohorts funding The CONSTANCES Cohort Study is supported by the Caisse Nationale d’Assurance Maladie (CNAM), the French Ministry of Health, the Ministry of Research, the Institut national de la santé et de la recherche médicale. CONSTANCES benefits from a grant from the French National Research Agency [Grant Number ANR-11-INBS-0002] and is also partly funded by MSD, AstraZeneca, Lundbeck and L’Oreal. The E3N-E4N cohort is supported by the following institutions: Ministère de l’Enseignement Supérieur, de la Recherche et de l’Innovation, INSERM, University Paris-Saclay, Gustave Roussy, the MGEN, and the French League Against Cancer. The NutriNet-Santé study is supported by the following public institutions: Ministère de la Santé, Santé Publique France, Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de la Recherche Agronomique (INRAE), Conservatoire National des Arts et Métiers (CNAM) and Sorbonne Paris Nord. The CEPH-Biobank is supported by the «Ministère de l’Enseignement Supérieur, de la Recherche et de l’Innovation»., SAPRIS-SERO Study Group: Fabrice Carrat, Marie Zins, Gianluca Severi, Mathilde Touvier, Hélène Blanché, Jean-François Deleuze, Xavier de Lamballerie, Clovis Lusivika-Nzinga, Gregory Pannetier, Nathanael Lapidus, Isabelle Goderel, Céline Dorival, Jérôme Nicol, Olivier Robineau, Sofiane Kab, Adeline Renuy, Stéphane Le-Got, Céline Ribet, Mireille Pellicer, Emmanuel Wiernik, Marcel Goldberg, Fanny Artaud, Pascale Gerbouin-Rérolle, Mélody Enguix, Camille Laplanche, Roselyn Gomes-Rima, Lyan Hoang, Emmanuelle Correia, Alpha Amadou Barry, Nadège Senina, Julien Allegre, Fabien Szabo de Edelenyi, Nathalie Druesne-Pecollo, Younes Esseddik, Serge Hercberg, Mélanie Deschasaux, Hélène Blanché, Jean-Marc Sébaoun, Jean-Christophe Beaudoin, Laetitia Gressin, Valérie Morel, Ouissam Ouili, Jean-François Deleuze, Laetitia Ninove, Stéphane Priet, Paola Mariela Saba Villarroel, Toscane Fourié, Souand Mohamed Ali, Abdenour Amroun, Morgan Seston, Nazli Ayhan, Boris Pastorino, ANR-20-COVI-0038,COVID-METAFLAM,Mise en place d'une approche metabolomique ciblée à réponse rapide pour modéliser les cinétiques d'évolution des médiateurs de l'inflammation chez les patients COVID-19 au cours de leur prise en charge dans les services de réanimations.(2020), Université Paris Cité - UFR Médecine [Santé] (UPCité UFR Médecine), and Demarquay, Sandrine

Subjects
Adult, [SDV] Life Sciences [q-bio], COVID-19 Vaccines, Multidisciplinary, SARS-CoV-2, [SDV]Life Sciences [q-bio], Antibody Formation, Vaccination, COVID-19, Humans, Antibodies, Viral
Abstract

Assessment of the intensity, dynamics and determinants of the antibody response after SARS-CoV-2 infection or vaccination in the general population is critical to guide vaccination policies. This study characterized the anti-spike IgG titers in 13,971 participants included in a French multicohort population-based serological survey on COVID-19 between April and October 2020 and followed-up with serological testing between May and October 2021. Eight follow-up profiles were defined depending on SARS-CoV-2 infection (0, 1 or 2) and COVID-19 vaccination (0, 1, 2 or 3). The anti-spike titer was lower in adults with no vaccination even in case of infection or reinfection, while it was higher in adults with infection followed by vaccination. The anti-spike titer was negatively correlated with age in vaccinated but uninfected adults, whereas it was positively correlated with age in unvaccinated but infected adults. In adults with 2 vaccine injections and no infection, the vaccine protocol, age, gender, and time since the last vaccine injection were independently associated with the anti-spike titer. The decrease in anti-spike titer was much more rapid in vaccinated than in infected subjects. These results highlight the strong heterogeneity of the antibody response against SARS-CoV-2 in the general population depending on previous infection and vaccination.

Published
2022

8. SARS-CoV-2 IgG seroprevalence surveys in blood donors before the vaccination campaign, France 2020-2021

Author

Gallian, Pierre, primary, Hozé, Nathanaël, additional, Brisbarre, Nadège, additional, Saba Villarroel, Paola Mariela, additional, Nurtop, Elif, additional, Isnard, Christine, additional, Pastorino, Boris, additional, Richard, Pascale, additional, Morel, Pascal, additional, Cauchemez, Simon, additional, and de Lamballerie, Xavier, additional

Published
2022
Full Text
View/download PDF

9. Susceptibility to monkeypox virus infection: seroprevalence of orthopoxvirus in 4 population samples; France, Bolivia, Laos and Mali

Author

Luciani, Léa, primary, Lapidus, Nathanaël, additional, Amroun, Abdennour, additional, Falchi, Alessandra, additional, Souksakhone, Chanthala, additional, Mayxay, Mayfong, additional, Dubot-Pérès, Audrey, additional, Saba Villarroel, Paola Mariela, additional, Diarra, Issa, additional, Koita, Ousmane, additional, Gallian, Pierre, additional, and de Lamballerie, Xavier, additional

Published
2022
Full Text
View/download PDF

10. A Cross-Sectional Study of Exposure Factors Associated with Seropositivity for SARS-CoV-2 Antibodies during the Second Epidemic Wave among a Sample of the University of Corsica (France)

Author

Decarreaux, Dorine, primary, Sevila, Julie, additional, Masse, Shirley, additional, Capai, Lisandru, additional, Fourié, Toscane, additional, Saba Villarroel, Paola Mariela, additional, Amroun, Abdennour, additional, Nurtop, Elif, additional, Vareille, Matthieu, additional, Pouquet, Marie, additional, Blanchon, Thierry, additional, de Lamballerie, Xavier, additional, Charrel, Rémi, additional, and Falchi, Alessandra, additional

Published
2022
Full Text
View/download PDF

11. High SARS-CoV-2 Prevalence among Healthcare Workers in Cochabamba, Bolivia

Author

Saba Villarroel, Paola Mariela, primary, Castro Soto, María del Rosario, additional, Undurraga, Verónica, additional, Sanz, Heydi, additional, Jaldín, Ana María, additional, Ninove, Laetitia, additional, Nurtop, Elif, additional, Pezzi, Laura, additional, Mohamed Ali, Souand, additional, Amroun, Abdennour, additional, Seston, Morgan, additional, and de Lamballerie, Xavier, additional

Published
2022
Full Text
View/download PDF

13. Orthopoxvirus Seroprevalence and Infection Susceptibility in France, Bolivia, Laos, and Mali.

Author

Luciani, Léa, Lapidus, Nathanaël, Amroun, Abdennour, Falchi, Alessandra, Souksakhone, Chanthala, Mayxay, Mayfong, Dubot-Pérès, Audrey, Saba Villarroel, Paola Mariela, Diarra, Issa, Koita, Ousmane, Gallian, Pierre, de Lamballerie, Xavier, and Villarroel, Paola Mariela Saba

Abstract

To determine a demographic overview of orthopoxvirus seroprevalence, we tested blood samples collected during 2003-2019 from France (n = 4,876), Bolivia (n = 601), Laos (n = 657), and Mali (n = 255) for neutralizing antibodies against vaccinia virus. In addition, we tested 4,448 of the 4,876 samples from France for neutralizing antibodies against cowpox virus. We confirmed extensive cross-immunity between the 2 viruses. Seroprevalence of antibodies was <1% in Bolivia, <5% in Laos, and 17.25% in Mali. In France, we found low prevalence of neutralizing antibodies in persons who were unvaccinated and vaccinated for smallpox, suggesting immunosenescence occurred in vaccinated persons, and smallpox vaccination compliance declined before the end of compulsory vaccination. Our results suggest that populations in Europe, Africa, Asia, and South America are susceptible to orthopoxvirus infections, which might have precipitated the emergence of orthopoxvirus infections such as the 2022 spread of monkeypox in Europe. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

14. Determining the best window for BNT162b2 mRNA vaccination for SARS-CoV-2 in patients with multiple sclerosis receiving anti-CD20 therapy

Author

Rico, Audrey, primary, Ninove, Laetitia, additional, Maarouf, Adil, additional, Boutiere, Clémence, additional, Durozard, Pierre, additional, Demortiere, Sarah, additional, Saba Villarroel, Paola Mariela, additional, Amroun, Abdennour, additional, Fourié, Toscane, additional, de Lamballerie, Xavier, additional, Pelletier, Jean, additional, and Audoin, Bertrand, additional

Published
2021
Full Text
View/download PDF

15. Corrigendum to: Antibody status and cumulative incidence of SARS-CoV-2 infection among adults in three regions of France following the first lockdown and associated risk factors: a multicohort study

Author

Carrat, Fabrice, primary, de Lamballerie, Xavier, additional, Rahib, Delphine, additional, Blanché, Hélène, additional, Lapidus, Nathanael, additional, Artaud, Fanny, additional, Kab, Sofiane, additional, Renuy, Adeline, additional, Szabo de Edelenyi, Fabien, additional, Meyer, Laurence, additional, Lydié, Nathalie, additional, Charles, Marie-Aline, additional, Ancel, Pierre-Yves, additional, Jusot, Florence, additional, Rouquette, Alexandra, additional, Priet, Stéphane, additional, Saba Villarroel, Paola Mariela, additional, Fourié, Toscane, additional, Lusivika-Nzinga, Clovis, additional, Nicol, Jérôme, additional, Legot, Stephane, additional, Druesne-Pecollo, Nathalie, additional, Esseddik, Younes, additional, Lai, Cindy, additional, Gagliolo, Jean-Marie, additional, Deleuze, Jean-François, additional, Bajos, Nathalie, additional, Severi, Gianluca, additional, Touvier, Mathilde, additional, and Zins, Marie, additional

Published
2021
Full Text
View/download PDF

16. Monoclonal antibodies for the treatment of COVID‐19 in a patient with high‐risk acute leukaemia

Author

Saultier, Paul, primary, Ninove, Laetitia, additional, Szepetowski, Sarah, additional, Veneziano, Mathilde, additional, Visentin, Sandrine, additional, Barlogis, Vincent, additional, Saba Villarroel, Paola Mariela, additional, Amroun, Abdennour, additional, Loosveld, Marie, additional, de Lamballerie, Xavier, additional, and Chambost, Hervé, additional

Published
2021
Full Text
View/download PDF

17. Impact of the Second Epidemic Wave of SARS-CoV-2: Increased Exposure of Young People

Author

Capai, Lisandru, primary, Masse, Shirley, additional, Fourié, Toscane, additional, Decarreaux, Dorine, additional, Canarelli, Jean, additional, Simeoni, Marie-Helene, additional, Amroun, Abdennour, additional, Mohammed-Ali, Souand, additional, Saba Villarroel, Paola Mariela, additional, Lamballerie, Xavier de, additional, Charrel, Rémi, additional, and Falchi, Alessandra, additional

Published
2021
Full Text
View/download PDF

18. Zika virus infection in pregnancy : a protocol for the joint analysis of the prospective cohort studies of the ZIKAlliance, ZikaPLAN and ZIKAction consortia

Author

Ades, A. E., Brickley, Elizabeth B., Alexander, Neal, Brown, David, Jaenisch, Thomas, Miranda-Filho, Democrito de Barros, Pohl, Moritz, Rosenberger, Kerstin D., Soriano-Arandes, Antoni, Thorne, Claire, Ximenes, Ricardo Arraes de Alencar, de Araujo, Thalia Velho Barreto, Avelino-Silva, Vivian, I, Bethencourt Castillo, Sarah Esperanza, Borja Aburto, Victor Hugo, Brasil, Patricia, Christie, Celia D. C., de Souza, Wayner Vieira, Gotuzzo, H. Jose Eduardo, Hoen, Bruno, Koopmans, Marion, Martelli, Celina Maria Turchi, Martins Teixeira, Mauro, Marques, Ernesto T. A., Miranda, Maria Consuelo, Montarroyos, Ulisses Ramos, Moreira, Maria Elisabeth, Morris, J. Glenn, Rockx, Barry, Saba Villarroel, Paola Mariela, Soria Segarra, Carmen, Tami, Adriana, Turchi, Marilia Dalva, Giaquinto, Carlo, de Lamballerie, Xavier, Wilder-Smith, Annelies, Ades, A. E., Brickley, Elizabeth B., Alexander, Neal, Brown, David, Jaenisch, Thomas, Miranda-Filho, Democrito de Barros, Pohl, Moritz, Rosenberger, Kerstin D., Soriano-Arandes, Antoni, Thorne, Claire, Ximenes, Ricardo Arraes de Alencar, de Araujo, Thalia Velho Barreto, Avelino-Silva, Vivian, I, Bethencourt Castillo, Sarah Esperanza, Borja Aburto, Victor Hugo, Brasil, Patricia, Christie, Celia D. C., de Souza, Wayner Vieira, Gotuzzo, H. Jose Eduardo, Hoen, Bruno, Koopmans, Marion, Martelli, Celina Maria Turchi, Martins Teixeira, Mauro, Marques, Ernesto T. A., Miranda, Maria Consuelo, Montarroyos, Ulisses Ramos, Moreira, Maria Elisabeth, Morris, J. Glenn, Rockx, Barry, Saba Villarroel, Paola Mariela, Soria Segarra, Carmen, Tami, Adriana, Turchi, Marilia Dalva, Giaquinto, Carlo, de Lamballerie, Xavier, and Wilder-Smith, Annelies

Abstract

Introduction: Zika virus (ZIKV) infection in pregnancy has been associated with microcephaly and severe neurological damage to the fetus. Our aim is to document the risks of adverse pregnancy and birth outcomes and the prevalence of laboratory markers of congenital infection in deliveries to women experiencing ZIKV infection during pregnancy, using data from European Commission-funded prospective cohort studies in 20 centres in 11 countries across Latin America and the Caribbean. Methods and analysis: We will carry out a centre-by-centre analysis of the risks of adverse pregnancy and birth outcomes, comparing women with confirmed and suspected ZIKV infection in pregnancy to those with no evidence of infection in pregnancy. We will document the proportion of deliveries in which laboratory markers of congenital infection were present. Finally, we will investigate the associations of trimester of maternal infection in pregnancy, presence or absence of maternal symptoms of acute ZIKV infection and previous flavivirus infections with adverse outcomes and with markers of congenital infection. Centre-specific estimates will be pooled using a two-stage approach. Ethics and dissemination: Ethical approval was obtained at each centre. Findings will be presented at international conferences and published in peer-reviewed open access journals and discussed with local public health officials and representatives of the national Ministries of Health, Pan American Health Organization and WHO involved with ZIKV prevention and control activities.

Published
2020
Full Text
View/download PDF

19. Zika virus infection in pregnancy: a protocol for the joint analysis of the prospective cohort studies of the ZIKAlliance, ZikaPLAN and ZIKAction consortia

Author

Ades, A E, primary, Brickley, Elizabeth B, additional, Alexander, Neal, additional, Brown, David, additional, Jaenisch, Thomas, additional, Miranda-Filho, Demócrito de Barros, additional, Pohl, Moritz, additional, Rosenberger, Kerstin D, additional, Soriano-Arandes, Antoni, additional, Thorne, Claire, additional, Ximenes, Ricardo Arraes de Alencar, additional, de Araújo, Thalia Velho Barreto, additional, Avelino-Silva, Vivian I, additional, Bethencourt Castillo, Sarah Esperanza, additional, Borja Aburto, Victor Hugo, additional, Brasil, Patrícia, additional, Christie, Celia D C, additional, de Souza, Wayner Vieira, additional, Gotuzzo H, Jose Eduardo, additional, Hoen, Bruno, additional, Koopmans, Marion, additional, Martelli, Celina Maria Turchi, additional, Martins Teixeira, Mauro, additional, Marques, Ernesto T A, additional, Miranda, Maria Consuelo, additional, Montarroyos, Ulisses Ramos, additional, Moreira, Maria Elisabeth, additional, Morris, J Glenn, additional, Rockx, Barry, additional, Saba Villarroel, Paola Mariela, additional, Soria Segarra, Carmen, additional, Tami, Adriana, additional, Turchi, Marília Dalva, additional, Giaquinto, Carlo, additional, de Lamballerie, Xavier, additional, and Wilder-Smith, Annelies, additional

Published
2020
Full Text
View/download PDF

20. Study protocol for the multicentre cohorts of Zika virus infection in pregnant women, infants, and acute clinical cases in Latin America and the Caribbean: the ZIKAlliance consortium

Author

Avelino-Silva, Vivian I., Mayaud, Philippe, Tami, Adriana, Miranda, Maria C., Rosenberger, Kerstin D., Alexander, Neal, Nacul, Luis, Segurado, Aluisio, Pohl, Moritz, Bethencourt, Sarah, Villar, Luis A., Viana, Isabelle F. T., Rabello, Renata, Soria, Carmen, Salgado, Silvia P., Gotuzzo, Eduardo, Guzman, Maria G., Martinez, Pedro A., Lopez-Gatell, Hugo, Hegewisch-Taylor, Jennifer, Borja-Aburto, Victor H., Gonzalez, Cesar, Netto, Eduardo M., Villarroel, Paola M. Saba, Hoen, Bruno, Brasil, Patricia, Marques, Ernesto T. A., Rockx, Barry, Koopmans, Marion, de Lamballerie, Xavier, Jaenisch, Thomas, Rosenberger, Kerstin Daniela, Morales, Ivonne, Tobian, Frank, Uhlmann, Lorenz, Schretzmann, Julius, Leege, Annika, Lins, Roberto D., Bispo de Filippis, Ana Maria, Machado Duarte, Ana Claudia, Espindola, Otavio de Melo, Bonaldo, Myrna, Damasceno, Luana, Mendes-Correa, Maria Cassia, Netto, Eduardo Martins, Tinedo, Maria Jose, La Rosa, Yenifer, Murillo, Marianela, Angel Villar, Luis, Consuelo Miranda, Maria, Lozano, Anyela, Mauricio Herrera, Victor, Gomez, Adriana, Margarita Gelvez, Rosa, Ortiz, Ricardo, Dimitrakis, Lady, Paola Salgado, Silvia, Regato Arrata, Mary, Guerra Allison, Humberto, Talledo, Michael, Saba Villarroel, Paola Mariela, Torres, Eric Martinez, Martinez Rodriguez, Pedro A., Alvarez Vera, Mayling, Galindo Santana, Belkis, Reyes, Alicia, Serrano Alvarez, Silvia, Ferriol Dorticos, Diana, Alpuche-Aranda, Celia, Gonzalez-Diaz, Esteban, Pavia-Ruz, Norma, Hugo Borja-Aburto, Victor, Grajales, Concepcion, Rojas, Teresita, Arriaga, Lumumba, Vallejos, Alfonso, Tynevez, Dominique, Thirion, Laurence, Drexler, Jan Felix, van Gorp, Eric, Avelino-Silva, Vivian I., Mayaud, Philippe, Tami, Adriana, Miranda, Maria C., Rosenberger, Kerstin D., Alexander, Neal, Nacul, Luis, Segurado, Aluisio, Pohl, Moritz, Bethencourt, Sarah, Villar, Luis A., Viana, Isabelle F. T., Rabello, Renata, Soria, Carmen, Salgado, Silvia P., Gotuzzo, Eduardo, Guzman, Maria G., Martinez, Pedro A., Lopez-Gatell, Hugo, Hegewisch-Taylor, Jennifer, Borja-Aburto, Victor H., Gonzalez, Cesar, Netto, Eduardo M., Villarroel, Paola M. Saba, Hoen, Bruno, Brasil, Patricia, Marques, Ernesto T. A., Rockx, Barry, Koopmans, Marion, de Lamballerie, Xavier, Jaenisch, Thomas, Rosenberger, Kerstin Daniela, Morales, Ivonne, Tobian, Frank, Uhlmann, Lorenz, Schretzmann, Julius, Leege, Annika, Lins, Roberto D., Bispo de Filippis, Ana Maria, Machado Duarte, Ana Claudia, Espindola, Otavio de Melo, Bonaldo, Myrna, Damasceno, Luana, Mendes-Correa, Maria Cassia, Netto, Eduardo Martins, Tinedo, Maria Jose, La Rosa, Yenifer, Murillo, Marianela, Angel Villar, Luis, Consuelo Miranda, Maria, Lozano, Anyela, Mauricio Herrera, Victor, Gomez, Adriana, Margarita Gelvez, Rosa, Ortiz, Ricardo, Dimitrakis, Lady, Paola Salgado, Silvia, Regato Arrata, Mary, Guerra Allison, Humberto, Talledo, Michael, Saba Villarroel, Paola Mariela, Torres, Eric Martinez, Martinez Rodriguez, Pedro A., Alvarez Vera, Mayling, Galindo Santana, Belkis, Reyes, Alicia, Serrano Alvarez, Silvia, Ferriol Dorticos, Diana, Alpuche-Aranda, Celia, Gonzalez-Diaz, Esteban, Pavia-Ruz, Norma, Hugo Borja-Aburto, Victor, Grajales, Concepcion, Rojas, Teresita, Arriaga, Lumumba, Vallejos, Alfonso, Tynevez, Dominique, Thirion, Laurence, Drexler, Jan Felix, and van Gorp, Eric

Abstract

Background: The European Commission (EC) Horizon 2020 (H2020)-funded ZIKAlliance Consortium designed a multicentre study including pregnant women (PW), children (CH) and natural history (NH) cohorts. Clinical sites were selected over a wide geographic range within Latin America and the Caribbean, taking into account the dynamic course of the ZIKV epidemic. Methods: Recruitment to the PW cohort will take place in antenatal care clinics. PW will be enrolled regardless of symptoms and followed over the course of pregnancy, approximately every 4 weeks. PW will be revisited at delivery (or after miscarriage/abortion) to assess birth outcomes, including microcephaly and other congenital abnormalities according to the evolving definition of congenital Zika syndrome (CZS). After birth, children will be followed for 2 years in the CH cohort. Follow-up visits are scheduled at ages 1-3, 4-6, 12, and 24 months to assess neurocognitive and developmental milestones. In addition, a NH cohort for the characterization of symptomatic rash/fever illness was designed, including follow-up to capture persisting health problems. Blood, urine, and other biological materials will be collected, and tested for ZIKV and other relevant arboviral diseases (dengue, chikungunya, yellow fever) using RT-PCR or serological methods. A virtual, decentralized biobank will be created. Reciprocal clinical monitoring has been established between partner sites. Substudies of ZIKV seroprevalence, transmission clustering, disabilities and health economics, viral kinetics, the potential role of antibody enhancement, and co-infections will be linked to the cohort studies. Discussion: Results of these large cohort studies will provide better risk estimates for birth defects and other developmental abnormalities associated with ZIKV infection including possible co-factors for the variability of risk estimates between other countries and regions. Additional outcomes include incidence and transmission estimates of

Published
2019

21. Monoclonal antibodies for the treatment of COVID‐19 in a patient with high‐risk acute leukaemia.

Author

Saultier, Paul, Ninove, Laetitia, Szepetowski, Sarah, Veneziano, Mathilde, Visentin, Sandrine, Barlogis, Vincent, Saba Villarroel, Paola Mariela, Amroun, Abdennour, Loosveld, Marie, de Lamballerie, Xavier, and Chambost, Hervé

Subjects
COVID-19, MONOCLONAL antibodies, ACUTE leukemia, COVID-19 treatment, SARS-CoV-2, TUMOR lysis syndrome, ACUTE diseases, KARYOTYPES
Abstract

Overall, these observations suggest that mAbs may be well tolerated for the treatment of SARS-CoV-2 infection in a patient undergoing therapy for high-risk leukaemia. Keywords: hematologic neoplasms; COVID-19; SARS-CoV-2; COVID-19 drug treatment; monoclonal antibodies EN hematologic neoplasms COVID-19 SARS-CoV-2 COVID-19 drug treatment monoclonal antibodies e1 e3 3 12/27/21 20220101 NES 220101 Adults and children with acute leukaemia are at high risk of serious illness and death from COVID-19, compared with the general population.1,2 Furthermore, delayed or interrupted leukaemia treatment due to SARS-CoV-2 infection may also result in poor prognosis, especially in aggressive forms of leukaemia. To mitigate the risk of a severe form of COVID-19, the patient was treated with a combination of the anti-SARS-CoV-2 mAbs bamlanivimab and etesevimab (off-label). [Extracted from the article]

Published
2022
Full Text
View/download PDF

23. Long-lasting Symptoms After an Acute COVID-19 Infection and Factors Associated With Their Resolution.

Author

Robineau, Olivier, Zins, Marie, Touvier, Mathilde, Wiernik, Emmanuel, Lemogne, Cedric, de Lamballerie, Xavier, Blanché, Hélène, Deleuze, Jean-François, Saba Villarroel, Paola Mariela, Dorival, Céline, Nicol, Jerome, Gomes-Rima, Roselyn, Correia, Emmanuelle, Coeuret-Pellicer, Mireille, Druesne-Pecollo, Nathalie, Esseddik, Younes, Ribet, Céline, Goldberg, Marcel, Severi, Gianluca, and Carrat, Fabrice

Published
2022
Full Text
View/download PDF

24. Long-Term Infectivity of Chikungunya Virus Stored in the Dark at 4°C.

Author

Pezzi L, Py O, Gilles M, Saba Villarroel PM, Diarra I, Fourié T, Gould EA, Gallian P, and de Lamballerie X

Subjects
Cell Line, Darkness, RNA, Viral, Chikungunya virus genetics, Cold Temperature, Specimen Handling
Abstract

We call into question the established dogma that viruses with envelopes and RNA genomes have limited stability by demonstrating the staggering long-term viability, ∼2 years, of chikungunya virus when stored in liquid environments at +4°C in the dark. We contend that our understanding of the infectivity of a variety of enveloped viruses requires a new approach to identify under standardized conditions the primary determinants of their viability.

Published
2021
Full Text
View/download PDF

25. Antibody status and cumulative incidence of SARS-CoV-2 infection among adults in three regions of France following the first lockdown and associated risk factors: a multicohort study.

Author

Carrat F, de Lamballerie X, Rahib D, Blanché H, Lapidus N, Artaud F, Kab S, Renuy A, Szabo de Edelenyi F, Meyer L, Lydié N, Charles MA, Ancel PY, Jusot F, Rouquette A, Priet S, Saba Villarroel PM, Fourié T, Lusivika-Nzinga C, Nicol J, Legot S, Druesne-Pecollo N, Esseddik Y, Lai C, Gagliolo JM, Deleuze JF, Bajos N, Severi G, Touvier M, and Zins M

Subjects
Adolescent, Adult, Antibodies, Viral, Child, Communicable Disease Control, France epidemiology, Humans, Incidence, Middle Aged, Seroepidemiologic Studies, COVID-19, SARS-CoV-2
Abstract

Background: We aimed to estimate the seropositivity to anti-SARS-CoV-2 antibodies in May-June 2020 after the first lockdown period in adults living in three regions in France and to identify the associated risk factors., Methods: Between 4 May 2020 and 23 June 2020, 16 000 participants in a survey on COVID-19 from an existing consortium of three general adult population cohorts living in the Ile-de-France (IDF) or Grand Est (GE) (two regions with high rate of COVID-19) or in the Nouvelle-Aquitaine (NA) (with a low rate) were randomly selected to take a dried-blood spot for anti-SARS-CoV-2 antibodies assessment with three different serological methods (ClinicalTrial Identifier #NCT04392388). The primary outcome was a positive anti-SARS-CoV-2 ELISA IgG result against the spike protein of the virus (ELISA-S). Estimates were adjusted using sampling weights and post-stratification methods. Multiple imputation was used to infer the cumulative incidence of SARS-CoV-2 infection with adjustments for imperfect tests accuracies., Results: The analysis included 14 628 participants, 983 with a positive ELISA-S. The weighted estimates of seropositivity and cumulative incidence were 10.0% [95% confidence interval (CI): 9.1%, 10.9%] and 11.4% (95% CI: 10.1%, 12.8%) in IDF, 9.0% (95% CI: 7.7%, 10.2%) and 9.8% (95% CI: 8.1%, 11.8%) in GE and 3.1% (95% CI: 2.4%, 3.7%) and 2.9% (95% CI: 2.1%, 3.8%) in NA, respectively. Seropositivity was higher in younger participants [odds ratio (OR) = 1.84 (95% CI: 1.79, 6.09) in <40 vs 50-60 years old and OR = 0.56 (95% CI: 0.42, 0.74) in ≥70 vs 50-60 years old)] and when at least one child or adolescent lived in the same household [OR = 1.30 (95% CI: 1.11, 1.53)] and was lower in smokers compared with non-smokers [OR = 0.71 (95% CI: 0.57, 0.89)]., Conclusions: Seropositivity to anti-SARS-CoV-2 antibodies in the French adult population was ≤10% after the first wave. Modifiable and non-modifiable risk factors were identified., (© The Author(s) 2021; all rights reserved. Published by Oxford University Press on behalf of the International Epidemiological Association.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results